
DNTH Stock Forecast & Price Target
DNTH Analyst Ratings
Bulls say
Dianthus Therapeutics Inc. is positioned for significant growth, with anticipated share price increases of 25%-30% under a logical base case scenario and a projected 15% increase based on an interim assessment upgrade. The pipeline highlights the potential of Claseprubart, which is expected to demonstrate greater potency and efficacy compared to riliprubart, further enhancing investor optimism surrounding the transition to Phase B of the CAPTIVATE trial. Additionally, a projected year-end cash balance of approximately $514 million underpins the company’s robust financial health, contributing to a revised target valuation of $55, up from $46, reflecting the overall favorable outlook for the stock.
Bears say
Dianthus Therapeutics Inc. faces significant financial challenges, particularly the risk of insufficient funding, which may hinder its ability to advance its therapeutic pipeline, including Claseprubart. The company's reliance on external capital raises concerns about its financial stability and the timing of its product development, especially if interim results are unsuccessful. These fundamental financial weaknesses contribute to a negative outlook on the company's stock performance.
This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DNTH Analyst Forecast & Price Prediction
Start investing in DNTH
Order type
Buy in
Order amount
Est. shares
0 shares